KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $2.8 million.

  • Neogenomics' Change in Accured Expenses fell 30.48% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 128.18%. This contributed to the annual value of $9.3 million for FY2024, which is 28.70% down from last year.
  • Neogenomics' Change in Accured Expenses amounted to $2.8 million in Q3 2025, which was down 67.82% from $8.6 million recorded in Q2 2025.
  • Neogenomics' Change in Accured Expenses' 5-year high stood at $13.6 million during Q2 2024, with a 5-year trough of -$23.0 million in Q1 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $4.0 million (2024), whereas its average is $976,000.
  • Within the past 5 years, the most significant YoY rise in Neogenomics' Change in Accured Expenses was 480.05% (2021), while the steepest drop was 648.95% (2021).
  • Over the past 5 years, Neogenomics' Change in Accured Expenses (Quarterly) stood at -$3.7 million in 2021, then spiked by 158.12% to $2.1 million in 2022, then spiked by 158.93% to $5.6 million in 2023, then skyrocketed by 84.64% to $10.3 million in 2024, then plummeted by 30.48% to $2.8 million in 2025.
  • Its Change in Accured Expenses was $2.8 million in Q3 2025, compared to $8.6 million in Q2 2025 and -$23.0 million in Q1 2025.